[go: up one dir, main page]

PL3383385T5 - Schematy dawkowania melflufenu w nowotworze złośliwym - Google Patents

Schematy dawkowania melflufenu w nowotworze złośliwym

Info

Publication number
PL3383385T5
PL3383385T5 PL16805792.5T PL16805792T PL3383385T5 PL 3383385 T5 PL3383385 T5 PL 3383385T5 PL 16805792 T PL16805792 T PL 16805792T PL 3383385 T5 PL3383385 T5 PL 3383385T5
Authority
PL
Poland
Prior art keywords
cancer
dosage regimens
melflufen
melflufen dosage
regimens
Prior art date
Application number
PL16805792.5T
Other languages
English (en)
Other versions
PL3383385T3 (pl
Inventor
Jakob LINDBERG
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3383385(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of PL3383385T3 publication Critical patent/PL3383385T3/pl
Publication of PL3383385T5 publication Critical patent/PL3383385T5/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16805792.5T 2015-12-01 2016-12-01 Schematy dawkowania melflufenu w nowotworze złośliwym PL3383385T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens
EP16805792.5A EP3383385B2 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer
PCT/EP2016/079511 WO2017093443A1 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer

Publications (2)

Publication Number Publication Date
PL3383385T3 PL3383385T3 (pl) 2021-05-04
PL3383385T5 true PL3383385T5 (pl) 2023-12-18

Family

ID=55177548

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16805792.5T PL3383385T5 (pl) 2015-12-01 2016-12-01 Schematy dawkowania melflufenu w nowotworze złośliwym

Country Status (27)

Country Link
US (3) US20180369141A1 (pl)
EP (3) EP3383385B2 (pl)
JP (2) JP6878431B2 (pl)
KR (2) KR20210092327A (pl)
CN (1) CN108289876A (pl)
AU (2) AU2016363591B2 (pl)
BR (1) BR112018010012A8 (pl)
CA (1) CA3003102C (pl)
CY (1) CY1123469T1 (pl)
DK (1) DK3383385T4 (pl)
ES (1) ES2828033T5 (pl)
FI (1) FI3383385T4 (pl)
GB (1) GB201521217D0 (pl)
HR (1) HRP20201632T4 (pl)
HU (1) HUE051525T2 (pl)
IL (2) IL259101A (pl)
LT (1) LT3383385T (pl)
MX (2) MX384724B (pl)
PL (1) PL3383385T5 (pl)
PT (1) PT3383385T (pl)
RS (1) RS60986B2 (pl)
RU (2) RU2020134307A (pl)
SG (1) SG11201803551YA (pl)
SI (1) SI3383385T2 (pl)
SM (1) SMT202000567T1 (pl)
WO (1) WO2017093443A1 (pl)
ZA (2) ZA201802816B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019362389B2 (en) * 2018-10-18 2024-12-12 Oncopeptides Innovation Ab Compounds containing deuterium
EP4588484A3 (en) * 2019-01-28 2025-10-15 Sanofi-Aventis U.S. LLC Methods of treating multiple myeloma
CN114025753A (zh) * 2019-04-03 2022-02-08 肿瘤多肽有限公司 用美氟芬治疗al淀粉样变性
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
EP4366721A1 (en) * 2021-07-08 2024-05-15 Oncopeptides Innovation AB Melflufen for use in the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
RS56462B1 (sr) * 2011-04-28 2018-01-31 Oncopeptides Ab Liofilizovani preparat citotoksičnih dipeptida
EP2909690B1 (en) 2012-10-22 2017-07-19 Parker Hannifin Manufacturing Sweden AB Joystick for utility vehicles
JP6284945B2 (ja) * 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
EA032775B1 (ru) * 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10

Also Published As

Publication number Publication date
JP2019501881A (ja) 2019-01-24
IL301019B2 (en) 2025-12-01
ZA201802816B (en) 2021-07-28
EP3383385A1 (en) 2018-10-10
CA3003102A1 (en) 2017-06-08
AU2016363591A1 (en) 2018-06-28
MX384724B (es) 2025-03-14
MX2018006706A (es) 2018-08-01
HRP20201632T1 (hr) 2021-01-08
ES2828033T5 (es) 2024-04-04
EP3903777A1 (en) 2021-11-03
ES2828033T3 (es) 2021-05-25
US20250144023A1 (en) 2025-05-08
EP3383385B1 (en) 2020-07-29
FI3383385T4 (fi) 2023-11-01
SMT202000567T1 (it) 2020-11-10
HUE051525T2 (hu) 2021-03-01
EP3750534A1 (en) 2020-12-16
ZA202102438B (en) 2025-08-27
SG11201803551YA (en) 2018-05-30
CA3003102C (en) 2022-09-13
DK3383385T3 (da) 2020-10-12
PL3383385T3 (pl) 2021-05-04
GB201521217D0 (en) 2016-01-13
US20220047507A1 (en) 2022-02-17
RS60986B2 (sr) 2023-12-29
RU2018123718A (ru) 2020-01-09
RS60986B1 (sr) 2020-11-30
PT3383385T (pt) 2020-10-26
RU2020134307A (ru) 2020-11-27
IL259101A (en) 2018-06-28
MX2021008738A (es) 2021-08-24
US20180369141A1 (en) 2018-12-27
HRP20201632T4 (hr) 2023-11-10
KR20180087254A (ko) 2018-08-01
LT3383385T (lt) 2020-12-28
KR20210092327A (ko) 2021-07-23
BR112018010012A8 (pt) 2019-02-26
IL301019A (en) 2023-05-01
CY1123469T1 (el) 2022-03-24
RU2018123718A3 (pl) 2020-04-02
AU2016363591B2 (en) 2020-12-10
CN108289876A (zh) 2018-07-17
NZ742548A (en) 2023-10-27
DK3383385T4 (da) 2023-11-06
WO2017093443A1 (en) 2017-06-08
EP3383385B2 (en) 2023-09-06
JP6878431B2 (ja) 2021-05-26
SI3383385T1 (sl) 2020-11-30
SI3383385T2 (sl) 2024-01-31
BR112018010012A2 (pt) 2018-11-21
JP2021088560A (ja) 2021-06-10
RU2734930C2 (ru) 2020-10-26
IL301019B1 (en) 2025-08-01
KR102279629B1 (ko) 2021-07-20
AU2021200436A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
IL254705A0 (en) Combination therapy for cancer
ZA201702382B (en) Combination therapy for cancer
IL249231A0 (en) Pharmaceutical combinations for cancer treatment
IL301019B2 (en) Malflufen dosage regimens for cancer
IL249898A0 (en) Combined cancer treatment
HUE055109T2 (hu) Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz
IL247083A0 (en) dose fgh–18
IL246761A0 (en) Combined cancer treatment
GB201418710D0 (en) Dosage regimen
GB201519734D0 (en) Cancer therapy
IL259097A (en) Combination therapy for cancer
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201617850D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201517643D0 (en) Dosage form for melatonin
GB201610502D0 (en) Dosage regimen
GB201511609D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201417819D0 (en) Agents for cancer therapy
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen